Skip to content

Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment

Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07089901
Acronym
DEDUCE
Enrollment
600
Registered
2025-07-28
Start date
2026-05-06
Completion date
2030-03-31
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking

Brief summary

Tobacco use is a chronic relapsing condition. That is, even with state-of-the-art treatment, \>70% of smoking cessation attempts end in a return to regular smoking. Research demonstrates that everyday environments associated with smoking trigger craving for cigarettes, provoke smoking, and lead to relapse. However, despite this knowledge, understanding of environmental correlates of smoking has been limited by a reliance on self-report, leading to imprecise information about the physical environments in which people live. To overcome this challenge, the research team has pioneered the development of digital envirotyping, which uses digital tools (e.g., sensors, cameras, artificial intelligence) to efficiently and accurately characterize and categorize environments with the goal of identifying environmental markers of behavior and health. Foundational to the digital envirotyping research is computer vision (CV), a type of artificial intelligence (AI) that enables computer systems to recognize objects and scenes in digital images, mimicking how humans perceive and understand visual information. With CV researchers can extract detailed and accurate information (i.e., objects and location types) about the everyday environments of people who smoke (PWS) and relate that information to smoking behavior. After validating the use of CV, the researchers used CV to develop enviromarkers of relapse risk. Importantly, they identified a novel enviromarker in which people at greater risk for relapse when they quit are exposed to a more consistent level of environment-related smoking risk as they move between their smoking and nonsmoking environments. Research is now needed to advance digital envirotyping and enviromarker development in the field of tobacco addiction. The study will recruit a diverse, national sample of n=500 adults who are interested in quitting smoking. For two weeks prior to quitting, they will undergo photoEMA in which they will take two pictures of their current environment when they smoke, and randomly 10 times per day resulting in \>300,000 images total. Cessation will be supported by nicotine replacement therapy (i.e., nicotine patch). The primary clinical outcome will be days to relapse. Specific aims are to (1) further develop, refine, and validate methods for efficient digital envirotyping at scale, (2) leverage CV and AI approaches to develop enviromarkers of smoking relapse, and (3) conduct analyses to increase understanding of environmental smoking risk in women and individuals with low socioeconomic status.

Interventions

DRUGtransdermal nicotine replacement therapy

All participants will receive transdermal nicotine replacement therapy (21 mg. patches)

Sponsors

Duke University
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 21 years of age or older; 2. Smoke ≥ 10 cigarettes/day 3. Smoking daily for ≥ 2 years, with a stable smoking pattern for the past 6 months; 4. Intention to quit smoking and set a target quit date in the next 1 month; 5. Have an iPhone or Android smartphone capable of running the photoEMA and iCO software 6. Positive Urine Cotinine Test

Exclusion criteria

1. Pregnant, breastfeeding, or planning to become pregnant during the course of the study; 2. Currently in smoking cessation treatment or current use of smoking cessation products; 3. Regular use (i.e. \>9 days/month) of non-cigarette nicotine-containing products (e.g. cigarillos, e-cigarettes); 4. Anticipating major life changes (e.g. new job, birth of a child) during the course of the study; 5. Unstable medical conditions; 6. Contraindication for nicotine replacement therapy.

Design outcomes

Primary

MeasureTime frameDescription
Average number of days to smoking relapseFrom quit date to 6-month follow-up (about 6.5 months)Participants will self-report smoking from quit date to the 6-month follow-up visit. Days to relapse will be defined as the first of seven consecutive days of smoking.

Secondary

MeasureTime frameDescription
Number of participants who self-report 7-day point prevalence abstinence1-month follow-up (around 1.5 months after beginning treatment)7-day point prevalence abstinence is defined as no smoking in the prior 7 days.

Countries

United States

Contacts

CONTACTLaura Van Althuis, MHA
deduce@duke.edu919-668-4312
CONTACTJasmin Walia
deduce@duke.edu919-668-0983
PRINCIPAL_INVESTIGATORFrancis J. McClernon, PhD

Duke University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026